NCT04566666 (SOLARES-PsO-1) is a Phase 2 clinical trial of SCD-044_Low Dose (Dose 1) in Moderate to Severe Plaque Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.

Who is sponsoring NCT04566666?

NCT04566666 is sponsored by Sun Pharmaceutical Industries Limited.

What drugs are being tested in NCT04566666?

Interventions in NCT04566666: Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2), SCD-044_High Dose (Dose 3).

What condition does NCT04566666 study?

NCT04566666 studies Moderate to Severe Plaque Psoriasis.

Is NCT04566666 still recruiting?

NCT04566666 is currently completed. Last updated 20 January 2026.

Are results published for NCT04566666?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-20 · How we verify

NCT04566666: SOLARES-PsO-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Completed Phase 2 Results posted Last updated 20 January 2026

What this trial tests

Phase 2 trial testing Placebo in Moderate to Severe Plaque Psoriasis in 263 participants. Completed in 27 August 2025.

Timeline

25 March 2021

Primary endpoint
20 November 2024

27 August 2025

Quick facts

Lead sponsor	Sun Pharmaceutical Industries Limited
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	263
Start date	25 March 2021
Primary completion	20 November 2024
Estimated completion	27 August 2025
Sites	50 locations across Georgia, Estonia, Poland, El Salvador, United States

Drugs / interventions tested

Placebo
SCD-044_Low Dose (Dose 1) — full drug profile →
SCD-044_Intermediate Dose (Dose 2) — full drug profile →
SCD-044_High Dose (Dose 3) — full drug profile →

Conditions studied

Moderate to Severe Plaque Psoriasis — all drugs for Moderate to Severe Plaque Psoriasis →

Sponsor

Sun Pharmaceutical Industries Limited — full company profile →

Who can join

18 and older, any sex, with Moderate to Severe Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Proportion of Subjects With at Least 75% Improvement in PASI (PASI 75) Primary · Week16

The subjects showing at least 75% improvement in Psoriasis Area and Severity Index score on a scale of 0-4 score. Higher score denotes more severe disease activity. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.

Group	Value	95% CI
Placebo of SCD-044 Product	14.0
SCD-044 Tablets_Dose 1	28.3
SCD-044 Tablets_Dose 2	23.0
SCD-044 Tablets_Dose 3	16.7

Investigator's Global Assessment (IGA) Score Secondary · Week 16

The subjects achieving predefined improvement (0 or 1) in Investigator's Global Assessment (IGA) of disease severity on a scale of 0 to 4 score with at least two-grade reduction from Baseline to Week 16. 0 indicates clear, while 1 indicates almost clear, while 4 is severe. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.

Group	Value	95% CI
Placebo of SCD-044 Product	0
SCD-044 Tablets_Dose 1	10.0
SCD-044 Tablets_Dose 2	9.8
SCD-044 Tablets_Dose 3	8.3

Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores Secondary · Week 52

The subjects achieving predefined improvement in Psoriasis Area and Severity Index (PASI) on a scale of 0-4 score. Higher score denotes more severe disease activity..

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	-3.58	± 1.813
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	-2.03	± 5.069
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	-17.18	± 7.685
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	-16.12	± 4.338
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	-17.11	± 6.570
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	-9.30	± 2.970
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	-20.87	± 16.686
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	-10.58	± 5.401
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	-11.62	± 6.010

Psoriasis Area and Severity Index (PASI) Response Rate Secondary · Week 16

Psoriasis Area and Severity Index (PASI50, PASI75, PASI90, and PASI100) response rate at Week 16. PASI50, PASI75, PASI90 and PASI100 are defined as 50%, 75%, 90% and 100% decrease from baseline in PASI correspondingly. The data represents the percentage of subject who achieved PASI 50, PASI 75, PASI 90, and PASI 100 at week 16.

PASI 50

Group	Value	95% CI
Placebo of SCD-044 Product	46.9
SCD-044 Tablets_Dose 1	47.5
SCD-044 Tablets_Dose 2	56.1
SCD-044 Tablets_Dose 3	50.0

PASI 75

Group	Value	95% CI
Placebo of SCD-044 Product	14.3
SCD-044 Tablets_Dose 1	28.8
SCD-044 Tablets_Dose 2	26.3
SCD-044 Tablets_Dose 3	17.4

PASI 90

Group	Value	95% CI
Placebo of SCD-044 Product	0
SCD-044 Tablets_Dose 1	6.8
SCD-044 Tablets_Dose 2	7.0
SCD-044 Tablets_Dose 3	2.2

PASI 100

Group	Value	95% CI
Placebo of SCD-044 Product	0
SCD-044 Tablets_Dose 1	3.4
SCD-044 Tablets_Dose 2	1.8
SCD-044 Tablets_Dose 3	2.2

Psoriasis Area and Severity Index (PASI) Response Rate Secondary · Week 52

Psoriasis Area and Severity Index (PASI50, PASI75, PASI90, and PASI100) response rate at Week 52 The data represents the percentage of subject who achieved PASI 50, PASI 75, PASI 90, and PASI 100 at week 16.

PASI 50

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	66.7
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	66.7
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	88.5
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	92.6
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	95.0
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	50.0
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	100.0
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	88.9
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	100.0

PASI 75

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	33.3
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	44.4
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	84.6
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	66.7
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	90.0
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	0
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	66.7
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	66.7
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	83.3

PASI 90

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	16.7
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	11.1
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	46.2
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	33.3
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	55.0
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	0
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	0
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	0
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	16.7

PASI 100

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	0
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	0
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	7.7
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	3.7
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	10.0
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	0
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	0
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	0
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	0

Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) at Week 16 Secondary · Week 16

At study week 0, 16, and 52; based on 11-item questionnaire, the symptoms and patient-observable signs in psoriasis will be scored using 0 to 10 rating scale (0-absent, 10-worst imaginable). The summary score is the sum of item scores (0-110), and a higher score indicates more severe disease- 0- best outcome 110- worst outcome

Group	Value	95% CI
Placebo of SCD-044 Product	-19.5	± 28.75
SCD-044 Tablets_Dose 1	-23.2	± 28.42
SCD-044 Tablets_Dose 2	-23.8	± 26.58
SCD-044 Tablets_Dose 3	-23.6	± 28.69

Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) at Week 52 Secondary · Week 52

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	-7.0	± 10.08
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	-9.6	± 17.21
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	-35.0	± 18.94
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	-33.6	± 25.03
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	-55.7	± 20.87
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	-26.0	± 59.40
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	-24.0	± 23.07
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	-12.7	± 34.29
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	-20.8	± 19.75

Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 Secondary · Week 16

At study week 0, 16, and 52; based on 10-item questionnaire on skin problems (0 to 3 scale). The scoring of each question is as follows: Very Much or Yes = 3, A lot = 2, A little = 2, Not relevant or Not at all or No = 0. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total score range: 0-30 (higher = greater impact). Interpretation bands: 0-1: No effect 2-5: Small effect 6-10: Moderate effect 11-20: Very large effect 21-30: Extremely large effect.

Group	Value	95% CI
Placebo of SCD-044 Product	-5.0	± 7.00
SCD-044 Tablets_Dose 1	-4.0	± 6.58
SCD-044 Tablets_Dose 2	-4.6	± 6.50
SCD-044 Tablets_Dose 3	-4.4	± 6.50

Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52 Secondary · Week 52

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	-1.5	± 1.22
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	-2.9	± 3.72
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	-7.8	± 5.28
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	-6.2	± 5.88
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	-10.7	± 4.00
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	-2.5	± 4.95
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	-3.0	± 6.24
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	-4.6	± 6.27
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	-4.2	± 4.54

Investigator's Global Assessment (IGA) Score Secondary · Week 52

The subjects achieving predefined improvement (0 or 1) in Investigator's Global Assessment (IGA) of disease severity on a scale of 0 to 4 score with at least two-grade reduction from Baseline to Week 52. 0 indicates clear, while 1 indicates almost clear, while 4 is severe. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	16.7
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	11.1
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	38.5
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	44.4
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	65.0
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	0
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	0
Part I Non-Responders:SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	22.2
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	0

Change From Baseline in Body Surface Area (BSA) at Week 16 Secondary · Week 16

At study weeks 16, and 52, the Investigator will assess % BSA affected with psoriasis.

Group	Value	95% CI
Placebo of SCD-044 Product	-7.21	± 9.608
SCD-044 Tablets_Dose 1	-8.32	± 16.194
SCD-044 Tablets_Dose 2	-9.57	± 12.983
SCD-044 Tablets_Dose 3	-9.63	± 12.794

Change From Baseline in Body Surface Area (BSA) at Week 52 Secondary · Week 52

At study weeks 16, and 52, the Investigator will assess % BSA affected with psoriasis.

Group	Value	95% CI
Part I Responders: Placebo to SCD-044 Tablets of Intermediate Dose (Dose 2)	-7.17	± 5.913
Part I Responders: Placebo to SCD-044 Tablets of High Dose (Dose 3)	-11.01	± 9.658
Part I Responders: SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)	-21.60	± 12.206
Part I Responders: SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)	-21.77	± 13.283
Part I Responders: SCD-044 High Dose (Dose 3) to High Dose (Dose 3)	-26.03	± 13.368
Part I Non-Responders: Placebo to SCD-044 Intermediate Dose (Dose 2)	-12.50	± 2.121
Part I Non-Responders: Placebo to SCD-044 High Dose (Dose 3)	-25.67	± 26.652
Part I Non-Responders: SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)	-19.00	± 13.285
Part I Non-Responders: SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)	-15.17	± 16.666

Adverse events — posted to ClinicalTrials.gov

Time frame: 56 Weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part 1- Placebo of SCD-044 Product

Serious: 1/64 (2%)

Deaths: 0/64

Part 1- SCD-044 Tablets_Dose 1

Serious: 0/71 (0%)

Deaths: 0/71

Part 1- SCD-044 Tablets_Dose 2

Serious: 2/69 (3%)

Deaths: 0/69

Part 1- SCD-044 Tablets_Dose 3

Serious: 0/59 (0%)

Deaths: 0/59

Placebo to SCD-044 Intermediate Dose (Dose 2)

Serious: 0/18 (0%)

Deaths: 0/18

Placebo to SCD-044 High Dose (Dose 3)

Serious: 0/22 (0%)

Deaths: 0/22

SCD-044 Low Dose (Dose 1) to Low Dose (Dose 1)

Serious: 0/32 (0%)

Deaths: 0/32

SCD-044 Intermediate Dose (Dose 2) to Intermediate Dose (Dose 2)

Serious: 0/36 (0%)

Deaths: 0/36

SCD-044 High Dose (Dose 3) to High Dose (Dose 3)

Serious: 0/20 (0%)

Deaths: 0/20

SCD-044 Low Dose (Dose 1) to High Dose (Dose 3)

Serious: 0/20 (0%)

Deaths: 0/20

SCD-044 Intermediate Dose (Dose 2) to High Dose (Dose 3)

Serious: 0/16 (0%)

Deaths: 0/16

Serious adverse events (3 terms)

Reaction	System	Part 1- Placebo of SCD-044…	Part 1- SCD-044 Tablets_Do…	Part 1- SCD-044 Tablets_Do…	Part 1- SCD-044 Tablets_Do…	Placebo to SCD-044 Interme…	Placebo to SCD-044 High Do…	SCD-044 Low Dose (Dose 1) …	SCD-044 Intermediate Dose …	SCD-044 High Dose (Dose 3)…	SCD-044 Low Dose (Dose 1) …	SCD-044 Intermediate Dose …
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Cerebral artery embolism	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (118 terms — click to expand)

Reaction	System	Part 1- Placebo of SCD-044…	Part 1- SCD-044 Tablets_Do…	Part 1- SCD-044 Tablets_Do…	Part 1- SCD-044 Tablets_Do…	Placebo to SCD-044 Interme…	Placebo to SCD-044 High Do…	SCD-044 Low Dose (Dose 1) …	SCD-044 Intermediate Dose …	SCD-044 High Dose (Dose 3)…	SCD-044 Low Dose (Dose 1) …	SCD-044 Intermediate Dose …
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Thrombocytosis	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Atrioventricular block first degree	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Atrioventricular block second degree	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Sinoatrial block	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Type V hyperlipidaemia	Congenital, familial and genetic disorders	—	—	—	—	—	—	—	—	—	—	—
Dry age-related macular degeneration	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Dry eye	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Iridocyclitis	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Macular oedema	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Myopia	Eye disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Dental caries	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Atrial fibrillation, Back pain, Cerebral artery embolism.

Data from ClinicalTrials.gov NCT04566666 adverse events section.

Sponsor's own description

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.
Drakos A, Torres T, Vender R. · · 2024 · cited 21× · PMID 38258121 · DOI 10.3390/pharmaceutics16010111
A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.
Drakos A, Vender R. · · 2022 · cited 15× · PMID 36319883 · DOI 10.1007/s13555-022-00840-9
Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.
Nitulescu G, Olaru OT, Andrei C, Nitulescu GM, et al · · 2025 · cited 2× · PMID 40864813 · DOI 10.3390/cimb47080659

Verify or expand the search:

Other recruiting trials for Moderate to Severe Plaque Psoriasis

Currently open trials in the same condition.

NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT06506916 — A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Sever · Phase 3 · recruiting
NCT06425549 — A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Ye · Phase 3 · recruiting

Other Sun Pharmaceutical Industries Limited trials

Trials by the same sponsor.

NCT06415279 — A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients · Phase 4 · completed
NCT06415292 — A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients · Phase 4 · completed
NCT06336603 — A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne · Phase 4 · completed
NCT06336629 — A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clinda · Phase 4 · completed
NCT06415305 — A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04566666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Pharmaceutical Industries Limited
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing